First Drug Candidate

PK - 048

There are no drugs that can provide a cure for Alzheimer's disease. Five drugs are on the market, but they at best alleviate symptoms for 6-12 months and offer no cure. Numerous other drugs are under development, but there have been repeated failures in recent clinical trials . The two main types of medication used to treat Alzheimer's disease are cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors include donepezil hydrochloride (Aricept), rivastigmine (Exelon) and galantamine (Reminyl). The NMDA receptor antagonist is memantine (Ebixa).

PharmaKure has patented PK-048 as its first repositioned drug candidate for Alzheimer's disease. The company is now moving into its commercialisation phase with a view to licensing and forging partnerships. Libraries of thousands of known drugs will be screened and any hits followed up.

PharmaKure's new drug candidate uses a novel receptor mechanism of action which inhibits the toxicity cascade induced by Aβ oligomerisation. In contrast, current drugs only alleviate symptoms by compensating for neuronal loss. Previous tests in primates have shown that the newly repositioned drug is orally active, non-toxic and crosses the blood-brain barrier, a crucial requirement for an Alzheimer's drug.

© 2013, Pharmakure Limited, All Rights Reserved
Drug Repositioning For Alzheimer's Disease: The Search For a Cure